Journal article
Idarucizumab for Dabigatran Reversal
Abstract
BACKGROUND: Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.
METHODS: We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent …
Authors
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW
Journal
The New England Journal of Medicine, Vol. 373, No. 6, pp. 511–520
Publisher
Massachusetts Medical Society
Publication Date
August 6, 2015
DOI
10.1056/nejmoa1502000
ISSN
0028-4793